Historically, the clinical staging of pancreatic cancer has centered on the surgical management of the primary tumor, because few effective chemotherapeutic agents were available and long-term ...

Mathis et al. aimed to determine the effect of multimodality therapy on recurrence and survival in patients with locally advanced colorectal cancer. Use of multimodality treatment led to excellent ...

Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a ...

New clinical practice guidelines for treating cancer of the esophagus and gastroesophageal junction (area where the esophagus meets the stomach) have been released. The guidelines include nine ...

Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a ...

Patients with stage III non-small-cell lung cancer (NSCLC) comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently ...

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and ...

Most patients receiving multimodality cancer care receive care from different practices. Therefore, episode-based payments in oncology must hold multiple providers accountable for costs and quality.

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Credit: US WorldMeds. Eflornihine is an ornithine decarboxylase inhibitor. The Food and Drug Administration (FDA) has approved Iwilfin ™ (eflornithine) to reduce the risk of relapse in adult and ...

Minaris will move its center for viral vector innovation to occupy space within CGT Catapult's collaborator laboratories in London and will work with CGT Catapult on the further development of ...